Patents by Inventor Shailendra Mandge
Shailendra Mandge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250170078Abstract: The present invention relates to oral pharmaceutical compositions comprising: (i) hydroxyurea at a concentration of about 10 mg/mL to about 100 mg/mL; (ii) at least one pharmaceutically acceptable liquid vehicle; (iii) one or more amino acids at a concentration of about 0.1 mg/mL to 10.0 mg/mL, and (iv) 0.001% to 10% of one or more pharmaceutically acceptable excipients, wherein the composition is in the form of a ready-to-use and safe-to-administer solution suitable for oral administration, wherein the hydroxyurea is dissolved in the liquid vehicle and the solution is homogeneous, and wherein the solution is stable, such that the level of carbamoyloxyurea in the solution is less than 0.5% w/w as measured by HPLC upon storage at 25° C./60% RH for at least 3 months, or at 2-8° C. for at least 12 months.Type: ApplicationFiled: January 24, 2025Publication date: May 29, 2025Applicant: Slayback Pharma LLC.Inventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Patent number: 12233049Abstract: The present invention relates to liquid pharmaceutical compositions of clonidine or its pharmaceutically acceptable salts thereof. Preferably, the liquid pharmaceutical compositions are suitable for oral administration, and are stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of clonidine at concentrations of 1 ?g/mL or more are provided. The present invention further relates to stable oral liquid compositions of clonidine, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by clonidine.Type: GrantFiled: July 15, 2022Date of Patent: February 25, 2025Assignee: SLAYBACK PHARMA LLCInventors: Shailendra Mandge, Harish Gunda, Naga Venkata Durga Prasad Ketha, Venkateshwar Reddy Keesara, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai
-
Patent number: 12213972Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.Type: GrantFiled: January 23, 2024Date of Patent: February 4, 2025Assignee: SLAYBACK PHARMA LLCInventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Sushant Omprakash Dube, Praveen Kumar Subbappa
-
Publication number: 20240197705Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.Type: ApplicationFiled: January 23, 2024Publication date: June 20, 2024Applicant: Slayback Pharma LLCInventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Sushant Omprakash Dube, Praveen Kumar Subbappa
-
Patent number: 11931370Abstract: The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.Type: GrantFiled: October 7, 2022Date of Patent: March 19, 2024Assignee: SLAYBACK PHARMA LLCInventors: Shailendra Mandge, Harish Gunda, Naga Venkata Durga Prasad Ketha, Venkateshwar Reddy Keesara, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai
-
Publication number: 20240050416Abstract: The present invention relates to stable pharmaceutical compositions comprising apixaban or its pharmaceutically acceptable salts thereof. The present invention further relates to a capsule composition comprising a therapeutically effective amount of apixaban solubilized or dispersed in a pharmaceutically acceptable carrier, wherein the therapeutically effective amount of apixaban ranges from about 0.5 mg/unit dosage form to about 50 mg/unit dosage form. The present invention also provides manufacturing processes thereof and use of the said compositions for prevention, treatment or prophylaxis of disorders in human patients in need thereof.Type: ApplicationFiled: July 24, 2023Publication date: February 15, 2024Applicant: Slayback Pharma LLCInventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian, Sumitra Ashokkumar Pillai, Sushant Omprakash Dube, Praveen Kumar Subbappa
-
Publication number: 20230301945Abstract: The present invention relates to stable oral pharmaceutical compositions in the form of a solution comprising: hydroxyurea at a concentration of about 10 mg/mL to about 500 mg/mL; at least one pharmaceutically acceptable liquid vehicle; and one or more amino acids selected from the group consisting of glycine, alanine, glutamic acid, L-arginine, lysine, L-cysteine, methionine and mixtures thereof, wherein the level of carbamoyloxyurea in the solution is less than 0.5 % w/w as measured by HPLC when the solution is stored at 25° C./60% RH for at least 3 months. The invention further relates to processes for the production of the compositions, methods for their administration, and their use for treatment of diseases treatable by hydroxyurea.Type: ApplicationFiled: February 2, 2023Publication date: September 28, 2023Applicant: Slayback Pharma LLCInventors: Shailendra Mandge, Venkateshwar Reddy Keesara, Harish Gunda, Naga Venkata Durga Prasad Ketha, Satheesh Balasubramanian ., Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Publication number: 20210085672Abstract: Described herein are solid, pharmaceutical compositions, dosage forms and methods of making and using the same, wherein the solid compositions comprise at least one high viscosity agent. The solid, high viscosity agent-comprising pharmaceutical compositions, when comprised of an opioid drug, can reduce the potential for abuse of such drug. The solid dosage forms are characterized by having a significantly reduced extractability of an opioid drug comprised therein upon contact of the dosage form with a solvent such as a typical household solvent. The solid dosage forms, following contact with a household solvent, such as an aqueous or alcoholic solvent, generate a high viscosity solution, thereby discouraging abuse of the resulting formulation via intravenous (IV) injection.Type: ApplicationFiled: July 25, 2018Publication date: March 25, 2021Inventors: Sindhuri Maddineni, Shailendra Mandge, Sourish Mukherjee, Vinod Balakrishnan Nair, Vijaya Srinivas Sekuboyina, Praveen Gaddam, Kevin J. Brodbeck, Ramakrishna Gadiraju, Xue Ge, Michael A. Eldon, Aleksandrs Odinecs, Satyanarayana Goda, Rajendra Tandale, Shiladitya Bhattacharya
-
Patent number: 9101541Abstract: The present invention discloses a stable solid pharmaceutical matrix composition comprising sirolimus or pharmaceutically acceptable salts thereof along with one or more sugars.Type: GrantFiled: April 25, 2011Date of Patent: August 11, 2015Assignee: Cadila Healthcare LimitedInventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Kiritkumar Maulik Panchal, Shubhashchandra Shailendra Mandge
-
Publication number: 20130095144Abstract: The present invention discloses a stable solid pharmaceutical matrix composition comprising sirolimus or pharmaceutically acceptable salts thereof along with one or more sugars.Type: ApplicationFiled: April 25, 2011Publication date: April 18, 2013Applicant: CADILA HEALTHCARE LIMITEDInventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Kiritkumar Maulik Panchal, Shubhashchandra Shailendra Mandge